Protein Degradation Therapy Market Report 2025

This protein degradation therapy market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The protein degradation therapy market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increase in prevalence of neurodegenerative diseases, increase in the success of targeted therapies, growth in investment in biotech innovation, rise in the need for personalized medicine, increase in the failure of conventional therapies to address certain diseases.

The protein degradation therapy market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing prevalence of chronic diseases, growing investment in biotech research, rising demand for targeted therapies, expansion of clinical trials, supportive regulatory environments. Major trends in the forecast period include development of next-generation PROTACs, integration of artificial intelligence and machine learning, emergence of combination therapies, development of personalized protein degradation therapies, and advancements in oral formulations and drug delivery systems.

The rising incidence of cancer is expected to drive the growth of the protein degradation therapy market. Cancer encompasses a variety of diseases characterized by uncontrolled cell proliferation and spread within the body. The increasing cancer rates are largely attributed to an aging population, along with lifestyle factors such as smoking, poor diet, insufficient physical activity, and growing obesity rates, which elevate the risk of various cancers. Protein degradation therapy is crucial in cancer treatment because it targets and removes specific proteins that support cancer growth and survival, potentially overcoming resistance to traditional therapies. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental agency, projected over 35 million new cancer cases by 2050, marking a 77% increase from the 20 million cases estimated in 2022. High human development index (HDI) countries are expected to see the greatest rise in new cases, with an additional 4.8 million cases predicted for 2050 compared to 2022 estimates. This increasing cancer burden is driving the growth of the protein degradation therapy market.

Key players in the protein degradation therapy market are forming strategic partnerships to develop innovative therapies, combine expertise, share resources, and accelerate the discovery and development of new drugs targeting disease-causing proteins. These partnerships leverage each company's strengths to achieve mutual benefits and success. For example, in June 2022, Merck KGaA, a Germany-based science and technology firm, entered into a multi-year research and licensing agreement with Proxygen, an Austria-based biotechnology company. Valued up to $2.55 billion, the partnership includes an upfront payment and potential milestone payments based on specific research, development, and commercial achievements. The collaboration aims to develop molecular glue degraders, leveraging Proxygen's expertise to reprogram cellular mechanisms for the selective elimination of disease-causing proteins, including those deemed "undruggable" by traditional methods.

In June 2024, Genexine, a South Korea-based biopharmaceutical company, merged with EPD Biotherapeutics for an undisclosed amount. This merger provides Genexine with essential talent and advanced technology, positioning it to lead in the global market. The integration of EPD Bio’s bioPROTAC technology with Genexine’s clinical and CMC development capabilities will facilitate the advancement of innovative new drugs. EPD Biotherapeutics, based in South Korea, specializes in the development of the protein degradation platform known as EPDeg.

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc.

North America was the largest region in the protein degradation therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein degradation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Protein degradation therapy is a treatment approach that focuses on the selective degradation of specific proteins within cells. This method employs small molecules, peptides, or other agents to induce the destruction of proteins that are either dysfunctional or contribute to disease. The objective is to reduce or eliminate harmful proteins associated with conditions such as cancer, neurodegenerative diseases, and autoimmune disorders.

Key products in protein degradation therapy include bavdegalutamide (ARV-110), vepdegestrant (ARV-471), among others. Bavdegalutamide, also known as ARV-110, is a novel therapy designed to target and degrade androgen receptors in prostate cancer cells. This therapy is utilized in fields such as oncology, neurodegenerative diseases, infectious diseases, and more, serving various end-users, including pharmaceutical companies, biotechnology firms, and academic and research institutions.

The protein degradation therapy market research report is one of a series of new reports that provides protein degradation therapy market statistics, including protein degradation therapy industry global market size, regional shares, competitors with a protein degradation therapy market share, detailed protein degradation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the protein degradation therapy industry. This protein degradation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The protein degradation therapy market consists of revenues earned by entities by providing services such as drug discovery and development, target validation, preclinical and clinical testing and targeted protein degradation screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein degradation therapy market also includes sales of degraders, E3 ligase ligands, degron tags, biochemical assay kits and cellular assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.